TY - JOUR T1 - Iterative surgical resections in non-small cell lung carcinoma JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2021.PA3405 VL - 58 IS - suppl 65 SP - PA3405 AU - Ahmet Üçvet AU - Serkan Yazgan AU - Özgür Samancılar AU - Soner Gürsoy AU - Ahmet Emin Erbaycu AU - Berna Kömürcüoğlu Y1 - 2021/09/05 UR - http://erj.ersjournals.com/content/58/suppl_65/PA3405.abstract N2 - Objectives: We reviewed our surgical preferences and the prognosis for recurrent and second primary tumors in patients who underwent surgical treatment for non-small cell lung carcinoma (NSCLC).Methods: Among patients who underwent segmentectomy or extended anatomical resection for primary NSCLC, those who underwent a second surgical resection between January 2010 and March 2020 due to recurrent or second primary tumor were included in the study. Operative mortality, survival, and prognostic factors were investigated.Results: In total, 77 cases were included: 31 (40.3%) underwent the second resection for the recurrent disease and 46 (59.7%) underwent the second resection for the second primary tumor. Postoperative mortality was detected in eight patients (10.4%). All patients with postoperative mortality were in this group and the difference between this group and those who underwent video-assisted thoracoscopic surgery (VATS) in at least one operation was statistically significant (p = 0.004). Mean and median survivals were 68.5 months and 57.8 months, respectively. The 5-year survival rate was 68.8% in patients under the age of 60 years, while it was 27.5% in patients aged 60 years and above (p = 0.004). The 5-year survival was 21.8% in patients with an interval of 36 months or less between two operations and 72.2%in those with a longer interval (p = 0.028).Conclusions: It is vital to identify patients eligible for recurrent surgical treatment. Our study shows that survival results similar to or better than primary NSCLC surgery can be obtained with lower mortality if more limited resections are performed via VATS, especially in young patients.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3405.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -